search button
Open Access

The auxiliary diagnostic value of prostate‑specific antigen and α‑methylacyl‑CoA racemase in prostate cancer

  • Authors:
    • Daijun Yang
    • Xiang Shi
    • Yu Lei
    • Xianrong Zhou
    • Qiuxiang Chen

  • View Affiliations

  • Published online on: May 21, 2020     https://doi.org/10.3892/ol.2020.11658
  • Pages: 1418-1422

  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer (PCa) is one of the most common types of malignant tumor, which places a major burden on the health of men, worldwide. A prerequisite to ensure good treatment outcomes for patients with PCa is an accurate diagnosis. The present study aimed to investigate the diagnostic value of prostate‑specific antigen (PSA) and α‑methylacyl‑CoA racemase (P504S) in PCa, using the tumor‑associated immunolabels. In total, clinical data was collected from 125 patients undergoing prostate biopsy or surgery between January 2015 and September 2019, and stratified into: PCa (45), benign prostatic hyperplasia (BPH) (60) and unconfirmed diagnosis (20). Immunohistochemistry analysis was performed to assess PSA and P504S expression levels in each group compared with that in the controls (the normal tissue in each group was the internal control). The results demonstrated that the expression level of P504S was significantly higher in the PCa group compared with that in the BPH group. Furthermore, no significant association was observed in the PCa group between PSA and P504S expression levels, and the Gleason grading groups. A total of 20 unconfirmed diagnoses was verified via PSA/P504S. Taken together, the results suggest that combination PSA and P504S have a positive effect in identifying prostate cancer. However, PSA and P504S still have limitations in their diagnosis and the final results need to be carefully and comprehensively analyzed, thus further studies are required to determine their diagnostic values.
View Figures
View References

Related Articles

Journal Cover

August-2020
Volume 20 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yang D, Shi X, Lei Y, Zhou X and Chen Q: The auxiliary diagnostic value of prostate‑specific antigen and α‑methylacyl‑CoA racemase in prostate cancer. Oncol Lett 20: 1418-1422, 2020
APA
Yang, D., Shi, X., Lei, Y., Zhou, X., & Chen, Q. (2020). The auxiliary diagnostic value of prostate‑specific antigen and α‑methylacyl‑CoA racemase in prostate cancer. Oncology Letters, 20, 1418-1422. https://doi.org/10.3892/ol.2020.11658
MLA
Yang, D., Shi, X., Lei, Y., Zhou, X., Chen, Q."The auxiliary diagnostic value of prostate‑specific antigen and α‑methylacyl‑CoA racemase in prostate cancer". Oncology Letters 20.2 (2020): 1418-1422.
Chicago
Yang, D., Shi, X., Lei, Y., Zhou, X., Chen, Q."The auxiliary diagnostic value of prostate‑specific antigen and α‑methylacyl‑CoA racemase in prostate cancer". Oncology Letters 20, no. 2 (2020): 1418-1422. https://doi.org/10.3892/ol.2020.11658